Gap Inc. (NYSE: GPS) was downgraded to Underperform from Neutral at Credit Suisse, and the firm cut its target price to $14 from $20.
Humana Inc. (NYSE: HUM) was started with a Buy rating and assigned a $316 target price at Mizuho.
L Brands Inc. (NYSE: LB) was downgraded to Underperform from Neutral and the target price was lowered to $14 from $22 at Credit Suisse.
Macy’s Inc. (NYSE: M) was downgraded to Underperform from Neutral at Credit Suisse, and the firm cut its target price to $12 from $19.
Newmark Group Inc. (NASDAQ: NMRK) was started with a Buy rating and assigned a $15 price objective (versus a $9.28 prior close) at Merrill Lynch.
Nordic American Tankers Ltd. (NYSE: NAT) was raised to In-Line from Underperform at Evercore ISI.
Pinterest Inc. (NYSE: PINS) was started as Neutral with a $29 target price at MKM Partners.
Snap Inc. (NYSE: SNAP) was reiterated as Neutral with a $14.75 target price (versus a $13.78 close) at Wedbush. The firm anticipated third-quarter earnings upside to be driven by ongoing engagement growth and advertiser demand. MKM Partners started Snap as Neutral with a $16 target price, and Merrill Lynch raised its rating from Neutral to Buy with an $18 price objective.
StoneCo Ltd. (NASDAQ: STNE) was started as Buy with a $42 target price at UBS.
Tandem Diabetes Care Inc. (NASDAQ: TNDM) was started with a Buy rating and assigned a $76 target price at Guggenheim.
Twitter Inc. (NYSE: TWTR) was started with a Neutral rating and assigned a $44 target price at MKM Partners.
UnitedHealth Group Inc. (NYSE: UNH) was started with a Buy rating and assigned a $180 target price at Mizuho.
In the waste management sector, KeyBanc Capital Markets downgraded Waste Management Inc. (NYSE: WM) to Sector Weight from Overweight and upgraded Waste Connections (NYSE: WCN) to Overweight from Sector Weight. Also, Merrill Lynch upgraded Republic Services Inc. (NYSE: RSG) from Neutral to Buy with a $95 target price.
Credit Suisse has issued earnings previews for big biotechs, and it now expects a solid quarter from continued execution. The firm sees upside opportunities despite the recent downturn in investor sentiment, with an increased focus on M&A being somewhat offset by increasing regulatory scrutiny of larger deals. Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) and Neurocrine Biosciences Inc. (NASDAQ: NBIX) are said to well-positioned ahead of the quarterly results. Amgen Inc. (NASDAQ: AMGN) could have a mixed quarter, while Biogen Inc. (NASDAQ: BIIB) could face a more challenging one.
Could mega-cap energy stocks deliver the best upside of all sectors in 2020 after not participating in the bull market?
Thursday’s top analyst upgrades and downgrades included Abbott Laboratories, CSX, IBM, Netflix, Occidental Petroleum, Whiting Petroleum, Amgen, Gilead Sciences, Merck, Pfizer and many more.